Analysts tout Akero's data as potentially the best for MASH ...

Analysts tout Akero's data as potentially the best for MASH treatment. Jefferies' Michael Yee labels it as 'best-in-class and best-in-disease therapeutic', while Cantor Fitzgerald's Prakhar Agrawal believes it dispels concerns about competition from drugs like Lilly's tirzepatide.